Related Experiment Videos
[Clinical study of Bi-Profenid in rheumatologic practice]
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|December 12, 1983
Summary
Bi-Profenid (150 mg) significantly improved pain and stiffness in 87.3% of patients with rheumatic diseases like osteoarthritis and rheumatoid arthritis. The drug demonstrated good tolerance with a low dropout rate, making it effective for managing chronic pain.
Area of Science:
- Rheumatology
- Pharmacology
Context:
- Multicenter study evaluating Bi-Profenid (150 mg) in 288 patients.
- Patients presented with common rheumatologic conditions: hip/knee arthrosis, rheumatoid arthritis, or ankylosing spondylarthritis.
Purpose:
- To assess the effectiveness and tolerance of Bi-Profenid (150 mg) twice daily for 30 days.
- To evaluate pain reduction and functional improvement in patients with degenerative and inflammatory rheumatic diseases.
Summary:
- Overall effectiveness reached 87.3% improvement based on pain scale assessment.
- Significant improvements noted in nocturnal pain, pain on mobilization, and walking distance for degenerative diseases.
- Inflammatory diseases showed significant improvements in nocturnal pain, morning stiffness, and rheumatoid arthritis functional indexes.
- Tolerance was rated outstanding or very good in 77.1% of patients, with a 7.6% dropout rate.
Impact:
- Bi-Profenid (150 mg) offers a well-tolerated and effective treatment option for managing pain and improving function in various rheumatic conditions.
- The study highlights the drug's potential to alleviate both nocturnal and activity-related pain, as well as morning stiffness.